Cosentyx polymyalgia rheumatica FDA approval infographic with REPLENISH remission data

Cosentyx Polymyalgia Rheumatica Approval: FDA Clears First IL-17 Biologic for PMR

The U.S. Food and Drug Administration has approved Cosentyx for polymyalgia rheumatica (PMR), Novartis announced on 17 November 2026, making secukinumab the first anti-IL-17 biologic cleared for the condition. The 150 mg dose is approved for adults whose PMR has not responded well enough to corticosteroids or who cannot complete a steroid taper. In the pivotal REPLENISH trial, 40.5% of patients on Cosentyx 150 mg were in sustained remission at one year versus 20.5% on placebo, roughly double the rate.

Key takeaways on Cosentyx polymyalgia rheumatica approval

  • FDA approval covers adults with PMR who respond inadequately to corticosteroids or cannot tolerate a steroid taper.
  • It is the 11th U.S. indication for Cosentyx and the first IL-17 inhibitor approved for PMR.
  • REPLENISH (381 patients, 27 countries) met its primary goal: sustained remission at week 52 of 40.5% vs 20.5%.
  • The approved regimen is 150 mg by injection, given weekly for five doses and then monthly alongside a steroid taper.
  • About 966,000 Americans live with PMR, and up to 40% relapse in the first year on steroids alone.

Why steroid-dependent PMR needed another option

Polymyalgia rheumatica is an inflammatory disease of adults over 50 that causes sudden pain and stiffness in the shoulders, neck and hips. It is especially common in people of Northern European descent. Low-dose prednisone usually brings fast relief, but the problem comes later: many patients flare as the dose is lowered, and some stay on steroids for years. Long-term glucocorticoid exposure is linked to osteoporosis, diabetes and cardiovascular disease, which matter a great deal in an older population that often already carries those risks.

Until now, the only biologic with a U.S. PMR label was Sanofi and Regeneron’s IL-6 blocker Kevzara (sarilumab), approved in 2023. Cosentyx gives rheumatologists a second steroid-sparing biologic that works through a different pathway, interleukin-17A, and one that many already prescribe for psoriatic arthritis and axial spondyloarthritis.

What REPLENISH showed, arm by arm

REPLENISH was a randomized, double-blind, placebo-controlled Phase III study that compared secukinumab 300 mg, secukinumab 150 mg and placebo, each combined with a 24-week steroid taper. Results were published in the New England Journal of Medicine and presented at EULAR 2026. Figures below come from the Novartis announcement and the published trial readout.

Week 52 measureCosentyx 300 mgCosentyx 150 mgPlacebo
Sustained remission41.2%40.6% (40.5% per Novartis)20.4%
Complete sustained remission (normal inflammatory markers)28.2%24.5%4.7%
Median time to escape or rescue therapy337 days282 days157 days
Annual steroid dose saved vs placeboabout 490 mgabout 410 mgn/a
Source: Novartis, REPLENISH Phase III data. Small differences reflect rounding between reports.

Two details stand out. First, the 300 mg and 150 mg arms performed almost identically on the primary endpoint, which helps explain why the FDA label starts at 150 mg. Second, the gap widens on the stricter measure: complete sustained remission, which requires normal blood inflammation markers, was about five times more frequent on the 150 mg dose than on placebo (24.5% vs 4.7%, by our calculation). REPLENISH principal investigator John Stone summed it up by saying secukinumab “doubled the likelihood of sustained remission while helping patients taper off steroids.”

How the regimen works in practice

Based on the dosing Novartis describes for PMR, patients receive 150 mg under the skin at weeks 0, 1, 2, 3 and 4, then once a month. Cosentyx is started alongside a tapering steroid course and can be continued on its own once prednisone is stopped. In Europe, the label allows the maintenance dose to rise to 300 mg depending on response. Patients should confirm the U.S. prescribing details with their rheumatologist, as the full label governs dose adjustments.

The practical promise is fewer steroid months, not a cure. About six in ten patients on the drug still did not reach sustained remission at week 52, so treatment decisions will hinge on how much steroid exposure a patient has already accumulated and how often they flare.

Safety signals to weigh

Novartis says the safety profile matched what is already known for Cosentyx. In the 150 mg arm, serious adverse events occurred in 15.9% of patients versus 14.2% on placebo. Hypersensitivity reactions such as eczema, rash and hives were reported in 14% versus 9%, and urinary tract infections in 13% versus 7%. One fatal case of cryptococcal meningitis, a serious fungal infection, was reported in a Cosentyx-treated patient. Infection vigilance is therefore important in an older population, many of whom are still on steroids during the taper.

Market context: a crowded but growing rheumatology space

PMR adds a new older-adult population to a franchise that already spans psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa. According to Acumen Research and Consulting, the global anti-rheumatics market was valued at USD 63.2 billion in 2022 and is projected to reach USD 81.5 billion by 2032, a 2.6% compound annual growth rate. Acumen reports that prescription drugs dominate the market, North America holds the largest share and Asia-Pacific is growing fastest. The report was last updated in March 2024, so its figures should be read as indicative.

For readers following immunology pipelines, our coverage of retatrutide in knee osteoarthritis shows how other musculoskeletal conditions are drawing big-pharma attention, and more approvals are tracked in our pharmaceutical news section.

What we still do not know

  • Head-to-head data: there is no trial comparing Cosentyx with Kevzara in PMR, so choosing between IL-17 and IL-6 blockade will rest on patient factors and payer coverage.
  • Durability: REPLENISH reports one-year outcomes; how long remission lasts after stopping the drug is not yet clear.
  • Access: Novartis has not detailed PMR-specific pricing or how insurers will position the drug against cheaper steroid-sparing options such as methotrexate.
  • Other markets: the EU approved the indication in October 2026; Japan and other regulators are still reviewing it.

FAQ

Is Cosentyx approved for polymyalgia rheumatica?

Yes. As of 17 November 2026 the FDA has approved Cosentyx 150 mg for adults with PMR who have an inadequate response to corticosteroids or cannot tolerate a steroid taper.

How well does Cosentyx work for PMR?

In REPLENISH, about 40% of patients on Cosentyx were in sustained remission at 52 weeks, compared with about 20% on placebo, while also using less steroid over the year.

What other biologic is approved for PMR?

Kevzara (sarilumab), an IL-6 receptor blocker, was approved for PMR in the U.S. in 2023. Cosentyx is the first IL-17 inhibitor with the indication.

What are the side effects of Cosentyx in PMR?

In the trial, hypersensitivity skin reactions and urinary tract infections were more common than on placebo, and one patient died of cryptococcal meningitis. Patients should discuss infection risk with their doctor.

Sources: Novartis announcement (17 Nov 2026); Novartis EU approval release; REPLENISH trial, NEJM. Market data: Acumen Research and Consulting. This article is for information only and is not medical advice. Last updated 17 November 2026.

Leave a Comment

Comments

No comments yet. Why don’t you start the discussion?

    Leave a Reply

    Your email address will not be published. Required fields are marked *